Nordic Field Medical Advisor Retina and Nipocalimab

For more than 130 years, diversity, equity & inclusion (DEI) have been part of our cultural fabric at Johnson & Johnson and woven into how we do business every day. Our commitment to respect the dignity and diversity of all is embedded in our Credo. We know that the success of our business depends on having the best talent in a workforce that reflects the diverse markets we serve around the world and an inclusive culture that values different perspectives and life experiences. That is why we in EMEA are working to create an inclusive environment where diverse backgrounds, perspectives and experiences are valued and each and every one of our people feels that they belong and can reach their potential. No matter who they are. Diversity, Equity & Inclusion at Johnson & Johnson means "You Belong". Role Purpose: The purpose of the Nordic Field Medical Advisor Retina and Nipocalimab is to develop and lead the Nordic medical strategy for Janssen's inherited retinal disease and nipocalimab portfolio. The Nordic Field Medical Advisor is responsible for the strategic, educational and informational aspects for this portfolio and to provide medical expertise for internal and external stakeholders in the Nordic countries. Key role activities: Serve as an expert within retinal disease, and indications for nipocalimab for external stakeholders in the Nordics Drive medical strategies for the retina and nipocalimab portfolio in the Nordic region. Provide relevant insights in the development of an EMEA medical strategy and co-create in applicable areas, like functional networks and squads.Take on responsibility for KOL management, planning and execution of medical events and activities on a Nordic level and in the countries. Develop, possess, and deliver expert knowledge on Janssen's retina and nipocalimab portfolio, including Nordic level coordination of activities and sharing of knowledge and insights internally and externally. Create and execute the local trainings and content. Develop close collaboration with GCO and have the Medical Affairs responsibility for Nordic clinical trial programs and activities. Co-create the IEGP for the retina and nipocalimab portfolio on Nordic level as well as local, under the leadership of the Medical Operations Lead. Drive relevant real world data initiatives in the Nordics to further facilitate diagnostic and treatment follow-up. Proactively assess the competitive landscape within the therapeutic areas. Compliance: Ensures alignment of all the activities with J&J Credo, applicable J&J procedures and policies including but not limited to those related with Health Care Compliance, Clinical Research and Pharmacovigilance, GCPs, Regulatory Regulations and local Legislation; Ensures safety reporting requirements (timely AE/PQC reporting) as set out in company policies and SOPs (Standard Operating Procedures) are met and appropriately managed when planning projects, developing materials, executing projects and contracting vendors; Ensures HCC and legal requirements (Fair Market Value, Transfer of Value rules, Promotional Materials rules) are fully understood, appropriately managed and complied with when planning projects, developing materials; Complies with designated SOP's and mandatory training for the role (Mandatory Training : MTP Matrix ) Complete annual Adverse Event and Quality Complaint Reporting Awareness training and HCC/FCPA Awareness training Report Adverse Events and Quality complaints in a timely way according to current guidelines/SOP Acts in accordance with Johnson & Johnson HCC requirements in interactions with Healthcare Professionals and Government Officials If commissioning contractors or third party organisations, perform Due Diligence where applicable, put compliant contracts in place and provide training, ensuring these individuals also act in accordance with Johnson & Johnson HCC requirements when interacting with Healthcare Professionals or Government Officials and ensure reporting of adverse events and quality complaints resulting from such collaborations (as above).